Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Share:
Related TEVA
Mylan Sends Letter to Teva CEO
Teva Announces Exclusive Launch of Generic Actonel Tablets in the United States
Perrigo buys Glaxo OTC drugs (Investor's Business Daily)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters